

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

1 **SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19**
2 **waves in The Gambia**

3

4 Ramatoulie E. Janha^{1∇}, Alasana Bah¹, Hawanatu Jah¹, Fatima Touray¹, Yahaya Idris¹, Saikou
5 Keita¹, Yassin Gaye¹, Samba Jallow¹, Tisbeh Faye-Joof¹, Baboucarr Njie¹, Rachel Craik^{2,3},
6 Nuredin I. Mohammed¹, Peter von Dadelszen², Umberto D'Alessandro¹, Anna Roca^{1♦}, and
7 the PRECISE Network*

8

9

10 **Author affiliations**

11 ¹Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical
12 Medicine, Atlantic Boulevard, Fajara, P.O. Box 273, Banjul, The Gambia

13 ²Department of Women and Children's Health, School of Life Course Science,
14 Faculty of Life Sciences and Medicine, King's College London, 5th Floor,
15 Becket House, 1 Lambeth Palace Road, London SE1 7EU, UK

16 ³Nuffield Department of Women's and Reproductive Health, University of Oxford,
17 Oxford, UK.

18

19 ♦Corresponding author: aroca@mrc.gm | Anna.Roca@lshtm.ac.uk (A.Roca)

20 ∇Alternative corresponding author: rjanha@mrc.gm | Ramatoulie.Janha@lshtm.ac.uk (R.E.
21 Janha)

22

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

23 **Highlights**

- 24 • High specificity of the IgM/IgG SARS-CoV-2 test using samples collected
25 prepandemic
- 26 • Very high (>90%) SARS-CoV-2 seroprevalence after third COVID-19 wave in The
27 Gambia
- 28 • High SARS-CoV-2 transmission contrasts with low number of COVID-19 reported
29 cases

30

31

32 **Abstract**

33 **Objectives**

34 SARS-CoV-2 transmission in Sub-Saharan Africa has probably been underestimated.
35 Population-based seroprevalence studies are needed to determine the extent of transmission
36 in the continent.

37 **Methods**

38 Blood samples from a cohort of Gambian pregnant women were tested for SARS-CoV-2 total
39 IgM/IgG before (*Pre-pandemic1*: October-December 2019 and *Pre-pandemic2*: February-
40 June 2020) and during the pandemic (*Post-wave1*: October-December 2020, *Post-wave2*:
41 May-June 2021; and *Post-wave3*: October-December 2021). Samples positive for total
42 SARS-CoV-2 IgM/IgG were tested for protein-specific antibodies.

43 **Results**

44 SARS-CoV-2 total IgM/IgG seroprevalence was 0.9% 95%CI (0.2, 4.9) in *Pre-pandemic1*;
45 4.1% (1.4, 11.4) in *Pre-pandemic2*; 31.1% (25.2, 37.7) in *Post-wave1*; 62.5% (55.8, 68.8) in
46 *Post-wave2* and 90.0% (85.1, 93.5) in *Post-wave3*. S-protein IgG and NCP-protein IgG
47 seroprevalence also increased at each *Post-wave* period. Although S-protein IgG and NCP-
48 protein IgG seroprevalence was similar at *Post-wave1*, S-protein IgG seroprevalence was
49 higher at *Post-wave2* and *Post-wave3*, [prevalence difference (PD) 13.5 (0.1, 26.8) and

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

50 prevalence ratio (PR) 1.5 (1.0, 2.3) in *Post-wave2*; and 22.9 (9.2, 36.6) and 1.4 (1.1, 1.8) in
51 *Post-wave3* respectively, $p < 0.001$].

52 **Conclusion**

53 SARS-CoV-2 transmission in The Gambia during the first three COVID-19 waves was high,
54 differing significantly from official numbers of COVID-19 cases reported. Our findings are
55 important for policy makers in managing the near-endemic COVID-19.

56

57 **Keywords**

58 Antibodies, COVID-19, Pregnancy, Seroprevalence, Sub-Saharan Africa, The Gambia

59

60 **INTRODUCTION**

61 SARS-CoV-2, the causative agent of the coronavirus disease 2019 (COVID-19), was first
62 identified in December 2019 in Wuhan, China [1]. SARS-CoV-2 was rapidly transmitted
63 globally, disrupting structures and systems; and causing millions of deaths. Globally, there
64 were 278.7M COVID-19 cases and 5.39M attributable deaths by December 2021 [2], 21
65 months after the World Health Organization (WHO) declared COVID-19 a pandemic [3].
66 Nigeria reported the first case in Sub-Saharan Africa (SSA) on 28 January 2020 [4]. The SSA
67 continent had the worst epidemiological modelling predictions of cases, hospitalisations and
68 deaths [5]. SARS-CoV-2 infection during pregnancy is of particular concern, as it increases
69 the rates of adverse maternal and neonatal outcomes [6]. Nevertheless, the impact of COVID-
70 19 in SSA was lower than expected, with 7.1 million cases and 155,300 deaths by December
71 2021, i.e., 2.5% of all cases and 2.9% of all deaths worldwide, despite Africa representing
72 17.4% of the global population [2].

73

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

74 Some underpinning factors in Africa, specifically in SSA, may explain the discrepancy
75 between predictions and actual burden. One of these is the limited capacity for diagnosis,
76 surveillance and testing for SARS-CoV-2, exacerbated by lack of systematic death
77 registrations in most SSA countries. Moreover, older age is a major risk factor for severe
78 COVID-19 and associated deaths. As the SSA population is young, i.e., in 2022, the median
79 age was 18.8 years, with 40% aged 14 years and younger, this may partially explain the low
80 number of reported deaths [7]. The communities' perceptions of COVID-19 and avoidance of
81 healthcare facilities [8] during the pandemic may have added to underdiagnosis of cases and
82 non-certification of COVID-19 as the cause of death. However, there is emerging evidence
83 that transmission in SSA has been at least as high or even higher than in other continents [9],
84 although these data should be interpreted with caution as some studies have important
85 limitations. Most of them do not represent the entire population, rather specific groups,
86 generally high risk groups [10]. In addition, SARS-CoV-2 prevalence may be overestimated
87 as SARS-CoV-2 antibodies may cross-react with other viral or parasitic antibodies in the
88 region, such as IgG antibodies against the spike and nucleocapsid proteins of different human
89 coronaviruses: HCoV-OC43, HKU-1, NL63 and 229E, as well as SARS and MERS [11], and
90 IgG directed against *Plasmodium falciparum* antigens where malaria is endemic [12]. To
91 overcome such challenges, the WHO recommends: (i) the use of multiple assays to confirm
92 seropositivity for SARS-CoV-2, including testing positive or equivocal samples with
93 neutralizing assays; (ii) repeated cross-sectional surveys to monitor the population serological
94 profile [13]; and (iii) testing assay specificity [14], as the multiple available assays consist of
95 a combination of serological tests targeting separate groups or monomers of specific antigens.
96
97 The Gambia is a small country situated in West Africa with a population of 2.57 million [15].
98 The objective of this study was to describe the seroprevalence of SARS-CoV-2 before (as a

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

99 measure of specificity) and following each of the first three waves among pregnant women
100 living in peri-urban and rural Gambia who participated in the PRECISE study [16]. In
101 general, pregnant women represent a healthy young adult population and seroprevalence in
102 this group should represent seroprevalence in adult healthy population.

103

104 **METHODS**

105 **COVID-19 and the National response in The Gambia**

106 The Gambia's first official COVID-19 case was reported on 16 March 2020 [17]. By
107 December 2021, The Gambia had registered three SARS-CoV-2 transmission waves dated:
108 first, July-September 2020; second, January 2021; and third, July 2021 (Figure 1). The first
109 and third waves were more intense, with higher peaks of official daily cases [18] with the
110 delta variant being the most frequent during the third wave [19]. The second wave concurred
111 with the global transmission of the delta/B.1.617.2 subtype variant, described in The Gambia
112 at the time [19].

113 Following the diagnosis of the first few official cases, a state of emergency was declared
114 [20]. Briefly, authorities prompted stringent response measures, including border closures
115 and a national lockdown (schools, worshipping grounds, and non-essential business
116 activities), initially for three months. Mandatory wearing of face masks and observing
117 physical distancing in public places were enforced [20]. Epidemiological surveillance
118 consisted of isolation, quarantine and Rt-PCR testing of suspected cases and travellers, and
119 contacts-tracing of confirmed cases. Surveillance, though, happened mostly carried out in the
120 urban Western Region. Vaccination coverage was very low; by December 2021, only 10.2%
121 of the total population (and <1% in our study area population) was fully vaccinated with 2
122 doses of Astrazeneca/Sinopharm or 1 dose of Johnson and Johnson [21].

123

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

124 **Study design – The PRECISE study**

125 This is an ancillary study of the PRECISE study (Pregnancy Care Integrating Translational
126 Science, Everywhere) [16], in which a pregnancy cohort was recruited in The Gambia, Kenya
127 and Mozambique, with the collection of extensive sociological and clinical data and
128 biological samples throughout woman’s pregnancy, until 6 weeks post delivery [16].

129

130 **PRECISE The Gambia**

131 In the Gambia, the study was implemented in Farafenni, North Bank Region, 116 km from
132 the capital city Banjul. Farafenni is divided into rural and urban areas and forms an important
133 commercial border with Senegal. Study participants were pregnant women attending
134 antenatal care at three health facilities: Maternal Newborn Child and Adolescent Health
135 Clinic in Farafenni (urban), Illiasa and Ngayen Sanjal (rural) health centres. Farafenni
136 General Hospital is the main referral hospital for the North Bank Region, population 225,516
137 [22], and Illiasa and Ngayen Sanjal are 17km west and 20km east of Farafenni, respectively.

138

139 The Gambian PRECISE cohort includes 1,253 pregnant women aged 16-49 years.
140 Participants were recruited at their first antenatal visit which could be at any time during their
141 pregnancy (mainly in 2nd trimester). A second antenatal visit was scheduled where possible
142 between 28 weeks’ gestation and the onset of labour (in 3rd trimester), and at least 4 weeks
143 after their booking visit. Women were then seen during their admission for giving birth if that
144 occurred in a participating healthcare centre. The last study visits occurred 6-weeks to 6-
145 months after delivery. At each study visit, blood samples were collected (between October
146 2019 and March 2022). As stated, demographic, epidemiological and clinical information
147 was collected during study visits. In our study population, vaccination status was not
148 collected.

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

149

150 **SARS-CoV-2 sero-prevalence study**

151 For the SARS-CoV-2 seroprevalence study presented here, we considered five sera collection
152 time periods that corresponded to the SARS-CoV-2 waves observed in The Gambia [19]: (i)
153 *Pre-pandemic1* (October - December 2019) before any case was detected in The Gambia;
154 (ii) *Pre-pandemic2* (February – June 2020) during which few cases were diagnosed but no
155 wave had yet started and the stringent 3-months national lockdown implemented; (iii) *Post-*
156 *wave1* (October – December 2020); *Post-wave2* (May – June 2021); and (v) *Post-wave3*
157 (October – December 2021) (Figure 1). The *Pre-pandemic1* period was included as an
158 additional step to determine specificity of the test used to measure the study primary endpoint
159 in our population as no SARS-CoV-2 transmission in The Gambia during these months is
160 expected.

161

162 For each time period, only one sample per woman was included although samples from the
163 same woman could have been selected for other periods.

164

165 **Study endpoints**

166 The primary endpoint was the SARS-CoV-2 seroprevalence (IgM and IgG against all SARS-
167 CoV-2 proteins) at each time-period as determined by the WANTAI. Secondary endpoints
168 include IgG seroprevalence to specific SARS-CoV-2 proteins (spike S1-subunit IgG and
169 nucleocapsid protein, NCP-IgG) (EUROIMMUN test).

170

171 **Serum collection and preparation**

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

172 Venous blood (6ml) was collected into serum separation tubes (BD Vacutainer SSTTM tubes,
173 Fisher Scientific), allowed to clot, and centrifuged at 2000g for 15 minutes. Separated sera
174 were kept at -80°C until serological analyses.

175

176 **Lab analysis and interpretation**

177 (a) **WANTAI immunoassay.** Sera were tested using the WANTAI SARS-CoV-2 Ab ELISA
178 Rapid Diagnostic Test kit (Wantai, Beijing, China) for qualitative detection of total IgM
179 and IgG against SARS-CoV-2 [23]. The WANTAI immunoassay microwell strips are
180 pre-coated with recombinant receptor-binding domain of the spike protein antigen
181 incorporated into a lateral flow ELISA design. The assay has a manufacturer-validated
182 sensitivity of 98.7% and specificity of 98.6% in participants from China [23]. An
183 independent clinical agreement validation of the WANTAI assay was conducted at the
184 Frederick National Laboratory for Cancer Research in the United States in July 2020
185 [23]. Each microwell plate had a blank calibrator, 50µl control, 100µl of serum. Following
186 two-steps of incubation at 37°C, washing, horse radish peroxidase-conjugation and
187 colourisation, absorbance was read at 450nm. After blanking and cut-off determination,
188 samples with absorbance/cut-off ratio ≥ 1 were positive for WANTAI whole IgM/IgG for
189 SARS-CoV-2.

190

191 (b) **EUROIMMUN immunoassay.** Two EUROIMMUN anti-SARS-CoV-2 ELISA test kits
192 (EUROIMMUN, US, Germany) [24, 25] were further performed on all WANTAI tested-
193 positive samples (Supplementary Figure 1). The EUROIMMUN microplates are pre-
194 coated separately with recombinant S1 domain of spike protein, for detecting IgG
195 antibodies against the S1-subunit; and modified NCP for detecting IgG against NCP. The
196 S1-IgG test has a sensitivity of 80% and a specificity of 98.5% [24]; and the NCP-IgG

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

197 test has a sensitivity of 94.6% and a specificity of 99.8% on European patients' sera [25].
198 Samples were diluted in sample buffer. Each well had 100µl of calibrators. Plates were
199 incubated, washed and enzyme-conjugated, followed by absorbance measurement at
200 450nm. Results for controls and samples were calculated considering the extinction of the
201 calibrator. The results were interpreted as: ratio<0.8: negative; ratio \geq 0.8 to <1.1:
202 borderline/indeterminate; and ratio \geq 1.1: positive.

203

204 **Statistical Analysis**

205 Categorical variables, including SARS-CoV-2 seroprevalence, were summarized using
206 proportions. Chi-square or Fisher's exact test were used where appropriate to test for
207 differences in proportions between time periods. Continuous variables were summarized
208 using median (interquartile range).

209 SARS-CoV-2 seroprevalence by WANTAI was expressed as the proportion [95%CI] of
210 WANTAI-positives to the total number of tested samples per time period. SARS-CoV-2
211 seroprevalence by EUROIMMUN was expressed as the proportion [95%CI] of
212 EUROIMMUN-positives to the total number of samples tested per time period.
213 EUROIMMUN borderline results were considered as negatives.

214

215 Prevalence ratios (PR) and prevalence differences (PD) between EUROIMMUN S-IgG and
216 NCP-IgG antibodies at each wave were calculated using generalized linear models (glm)
217 with robust standard errors. We used Bonferroni method throughout to account for multiple
218 comparisons (due to multiple time periods).

219

220 To determine the proportions of new infections at each post-wave period (considering any
221 seroprevalence by WANTAI), our assumptions were that after one infection women

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

222 remained seropositive throughout the study and women tested at each time period represented
223 a random sample from the PRECISE cohort. Therefore, we calculated the percentage of new
224 infections as the increased prevalence in the population at risk (percentage of population
225 uninfected in the preceding wave). All data management and analyses for this study were
226 performed using Stata version 17.0 [26].

227

228 **RESULTS**

229 **Participants' baseline characteristics**

230 803 women were included in the five sera collection time periods, with 112 in *Pre-*
231 *pandemic1*, 73 in *Pre-pandemic2*, 209 in *Post-wave1*, 208 in *Post-wave2* and 201 in *Post-*
232 *wave3*. Baseline characteristics of women were similar at the different time points, with a
233 median age of 26 years, both Mandinkas and Wolofs being the most common ethnic groups,
234 median household size of 9 individuals per household and median parity 2-4 children per
235 woman (Supplementary Table 1).

236

237 **SARS-CoV-2 sero-prevalence (WANTAI)**

238 Overall, SARS-CoV-2 seroprevalence was low in the *Pre-pandemic1 period* at 0.9% 95%CI
239 (0.2, 4.9) and the *Pre-pandemic2 period* at 4.1% (1.4, 11.4) (Table 1a, Figure 2a). SARS-
240 CoV-2 seroprevalence significantly increased over time, from 31.1% (25.2, 37.7) in the *Post-*
241 *wave1 period* to 90.0% (85.1, 93.5) in the *Post-wave3 period* ($p<0.001$, Figure 2a, Table 1a
242 and Table 1b). The stratified analysis of seroprevalence shows similar results for urban and
243 rural Farafenni (Table 1a, Figure 2b).

244

245 **SARS-CoV-2 protein specific sero-prevalence: Spike (S1-subunit protein) specific IgG**
246 **and nucleocapsid -NCP protein specific IgG**

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

247 S-protein specific SARS-CoV-2 sero-prevalence increased significantly in the post-wave
248 periods, from 16.3% (11.9, 21.9) in the *Post-wave1 period* to 74.6% (68.2, 80.1) in the *Post-*
249 *wave3 period*. Increase of sero-prevalence between *Post-wave1*, -2 and -3 was significant for
250 all comparisons, in terms of PR and PD (Supplementary Table 2, Figure 3).

251 Similarly, NCP-protein specific SARS-CoV-2 sero-prevalence increased significantly in the
252 *post-wave* periods, from 12.9% (9.0, 18.1) in the *Post-wave1 period* to 51.7% (44.9, 58.6) in
253 the *Post-wave3 period*, with significant increase for each comparison, in terms of PR and
254 PD (Supplementary Table 2, Figure 3).

255 SARS-CoV-2 protein specific sero-prevalence was similar for S-protein IgG and NCP-
256 protein IgG in the *Post-wave1 period* (p=1.000 for PR and PD). However, SARS-CoV-2
257 protein specific seroprevalence was higher for S-protein IgG than NCP-protein IgG in the
258 *Post-wave2 period* PR 1.5 95%CI (1, 2.3), p=0.061, PD 13.5 95%CI (0.1, 26.8), p=0.047
259 and the *Post-wave3 period* PR 1.4 95%CI (1.1, 1.8), p<0.001, PD 22.9 95%CI (9.2, 36.6),
260 p<0.001, showing that the difference between S-protein IgG and N-protein IgG increases
261 after the *Post-wave1 period* (Supplementary Table 2).

262

263 **New infections by post-wave period**

264 During *Post-wave2*, 45.6% of the women at risk were newly infected. This percentage was up
265 to 73.3% in the *Post-wave3* period (Figure 4).

266

267

268 **DISCUSSION**

269 SARS-CoV-2 sero-prevalence increased significantly among pregnant women living in
270 Farafenni; between October 2019, before the first case of COVID-19 was diagnosed in The
271 Gambia, and December 2021, after 3 epidemic waves. Most women acquired antibodies

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

272 against SARS-CoV-2, indicating very high transmission in this area, and probably across The
273 Gambia. The discrepancy between such high seroprevalence and the relatively modest
274 number of reported COVID-19 cases is remarkable.

275

276 The delayed start of the epidemic in The Gambia was probably due to the measures taken by
277 the Ministry of Health by declaring the state of emergency in March 2020, soon after the first
278 SARS-CoV-2 case was diagnosed in The Gambia [20]. However, the stringent non-
279 pharmaceutical interventions lasted only until June 2020, just before the first wave.
280 Therefore, it is not surprising that in October-December 2020, after the first wave, about a
281 third of pregnant women had SARS-CoV-2 antibodies as adherence to any non-
282 pharmaceutical interventions (e.g., physical distancing, wearing of facemasks, decreasing
283 mass gatherings at public places) from the moment the state of emergency was relaxed and
284 the borders opened was low [17]. These findings confirm that SARS-CoV-2 transmission in
285 The Gambia was much higher than those reported officially about COVID-19 cases and
286 deaths. Indeed, a study analysing the incidence of SARS-CoV-2 after the first wave among
287 staff with standard risk of infection (excluding those working with infected patients) working
288 at the MRC Unit The Gambia indicated that transmission was 80-fold higher than officially
289 reported [20]. Interestingly, the high transmission of SARS-CoV-2 during the first wave did
290 not translate in overall excess mortality, confirming that the epidemic has been milder than in
291 other regions. Nevertheless, in Farafenni, it was detected an excess mortality among the
292 vulnerable 65+ years age-group [27]. Transmission became even easier for the virus in the
293 second and third waves when nationwide restrictions were eased further [17]. The third wave
294 in The Gambia was dominated by the highly transmissible delta variant [19]. This is shown
295 by the estimated 73.3% of the population at risk infected during this wave, increasing the
296 overall SARS-CoV-2 seroprevalence to 90%.

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

297

298 The high SARS-CoV-2 total antibodies' prevalence described in our study is comparable to
299 that reported from other West African countries at similar times. In Senegal, national SARS-
300 CoV-2 seroprevalence was 28.1% in October-November 2020, at the end of their first
301 transmission wave [28], similar to the prevalence in Farafenni at the same time. Furthermore,
302 in Togo, nationwide seroprevalence in May-June 2021 was 64.3%, which is similar to the
303 prevalence in Farafenni after the second wave [29].

304

305 The WHO-procured WANTAI test for standardisation is widely used in Africa [9]. We
306 measured the specificity of the test in our study population by analysing samples collected
307 before the detection of any COVID-19 case outside Wuhan (our *Pre-pandemic1* period
308 covers the period October to December 2019), and were able to confirm the high specificity
309 of this test in our population as only 1 out of 112 samples were positive (likely, a false
310 positive) in the *Pre-pandemic1 period*. A major strength of this study is that pre- and post-
311 epidemic samples were collected from the same population and, therefore, were comparable,
312 and provides confidence that seroprevalence was estimated correctly. This is important as
313 other studies carried out in SSA suggested that the high prevalence of SARS-CoV-2
314 antibodies in some countries were due to the high cross-reactivity of samples and thus the
315 low specificity of the tests used [11]. Four ELISA tests had lower specificity when used on
316 African samples than European or American samples [30]. These tests included the two
317 EUROIMMUN tests used in this study but not the WANTAI test. We did not determine the
318 specificity of the EUROIMMUN assay as only samples positive by WANTAI were
319 subsequently tested using the SARS-CoV-2 protein specific IgG tests (S-protein and NCP-
320 protein). We also included in our analysis a time period after the first cases had been detected
321 in The Gambia, but before the first wave of the pandemic was officially declared (*Pre-*

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

322 *pandemic2*). The seroprevalence in this period did not differ significantly from the *Pre-*
323 *pandemic1 period*, indicating that transmission was probably low before the first wave was
324 detected even in Farafenni, where the first wave may have started due to the porous border
325 with Senegal [19] .

326

327 The lower prevalence observed against S-protein IgGs and NCP-protein IgGs compared with
328 whole SARS-CoV-2 IgM/IgG is expected as the latter includes more epitopes and antibody
329 types. Notwithstanding, the IgG prevalence against the S-protein and NCP-protein was high
330 and increasing over time with the occurrence of the COVID-19 waves. Interestingly, the
331 prevalence of NCP-protein IgG is significantly lower than that of the S-protein IgG in the
332 *Post-wave2 period* and *Post-wave3 period*, but not in the *Post-wave1 period*. These results
333 suggest antibodies against S-protein are lasting longer than those against the NCP-protein
334 [31], as the latter wane sooner while the former accumulates. Indeed, the first exposure to
335 SARS-CoV-2 of women whose samples were collected in October - December 2020 was
336 during the first wave and thus they had similar levels of S- and NCP-protein specific IgGs.
337 However, during subsequent waves, some women were probably re-infected while others
338 were infected for the first time and thus S-protein specific IgG had a higher prevalence than
339 NCP-protein specific IgG after the second and third waves. An analysis of samples of
340 approximately 39,000 individuals in a clinical laboratory in the United States to monitor
341 SARS-CoV-2 S-protein and NCP-protein durability reveals that both protein-specific IgGs
342 reached a peak of 90% positivity at 21 days post-index [32]. However, by 10 months the
343 NCP-protein IgG seropositivity declined to 68.2%, whilst the S-protein IgG remained at a
344 rate of 87.8%. The data describing longitudinal monitoring of SARS-CoV-2 humoral
345 antibody responses mostly come from high-income countries. Our observation of a shorter
346 durability of NCP-protein IgG than S-protein IgG is in line with those observations.

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

347

348 We need to acknowledge some limitations of our study. The surveys were conducted in a
349 homogeneous population, in a specific region and a relatively narrow age group. Therefore, it
350 is not possible to extrapolate these results to other age groups or regions. However, pregnant
351 women are generally a healthy population who routinely visit hospitals for antenatal care and
352 institutional delivery [33] and, thus, are often used as a proxy group for the whole population.
353 In general, they continue doing similar activities than before pregnancy. Prevalence in rural
354 and urban Farafenni was very similar, possibly suggesting such prevalence may be
355 consistent across the country. In addition, the differences between S-protein specific IgG and
356 NCP-protein specific IgG sero-prevalence in *Post-waves* -2 and -3 may be confounded by
357 vaccination as vaccination only generates antibody responses towards the S-protein.
358 Although vaccination status was not available for study women, it is worth noting that
359 vaccine coverage in the study area was less than 1% by December 2021[21].

360

361 In conclusion, SARS-CoV-2 transmission in The Gambia was high during the first three
362 COVID-19 waves. The high seroprevalence observed in our study combined with the former
363 data of no excess mortality in The Gambia in 2020 [27] confirms that the clinical severity of
364 infection during the COVID-19 epidemic has been milder in The Gambia than in other
365 countries. Our results are important for policy makers to take decisions on how to manage the
366 epidemic virus that is progressing into an endemic virus. Our study confirms that in settings
367 with limited laboratory capacity, seroprevalence studies are a powerful tool to understand the
368 real burden of SARS-CoV-2 transmission.

369

370 **Authors' contributions and other declarations**

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

371 AR conceptualized and designed the study. REJ, UDA and AR interpreted the data and wrote
372 the manuscript. AB and TFJ coordinated the laboratory analysis and edited the manuscript.
373 HJ contributed to conception of the study, acquisition of data, and editing of the manuscript.
374 NIM conducted the data analysis, and contributed to the interpretation of results and editing
375 the manuscript. FT and YI contributed to data acquisition, curation, and editing the
376 manuscript. SK, YG and SJ contributed to data acquisition, analysis and interpretation, and
377 editing of the manuscript. BN contributed to data curation and management, and editing the
378 manuscript. RC and PvD contributed to the study conception, interpretation of data, and
379 editing of the manuscript. The final draft was reviewed and approved by all authors.

380

381 **Acknowledgements**

382 We would like to express sincere thanks to the study participants residing in Farafenni. We
383 thank Thomas Mendy for data management oversight and Fatoumata Kongira heading the
384 field and clinical PRECISE team in sensitization and recruitment. We thank all Gambian
385 PRECISE staff for data and sample collection, sample processing and storage. We thank the
386 MRCG at LSHTM platform departments for research support. We are grateful to WHO for
387 providing the WANTAI test kits.

388

389 *The PRECISE Network authorship:

390 King's College London (Laura A. Magee, Hiten Mistry, Marie-Laure Volvert, Thomas
391 Mendy, Lucilla Poston, Jane Sandall, Rachel Tribe, Sophie Moore, Tatiana Salisbury); Aga
392 Khan University, Nairobi (Marleen Temmerman, Angela Koech, Patricia Okiro, Geoffrey
393 Omuse, Grace Mwashigadi, Consolata Juma, Isaac Mwaniki, Alex Mugo Joseph Mutunga,
394 Moses Mukhanya, Onesmus Wanje, Marvin Ochieng, Emily Mwadime); Centro de
395 Investigação de Saúde de Manhiça (Esperança Sevene, Corssino Tchavana, Salesio

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

396 Macuacua, Anifa Vala, Helena Boene, Lazaro Quimice, Sonia Maculuve, Eusebio Macete,
397 Inacio Mandomando, Carla Carillho); Donna Russell Consulting (Donna Russell); London
398 School of Hygiene and Tropical Medicine (Hannah Blencowe, Veronique Filippi, Joy Lawn,
399 Matt Silver, Joseph Waiswa, Ursula Gazeley); Midlands State University (Prestige Tatenda
400 Makanga, Liberty Makacha, Reason Mlambo), MRC Unit The Gambia at LSHTM (Andrew
401 M. Prentice, Melisa Martinez-Alvarez, Brahim Diallo, Abdul Sesay, Sambou Suso, Yahaya
402 Idris, Fatoumata Kongira, Modou F.S. Ndure, Lawrence Gibba, Abdoulie Bah, Yorro Bah.);
403 University of Oxford (Alison Noble, Aris Papageorghiou); St George's, University of
404 London (Judith Cartwright; Guy Whitley, Sanjeev Krishna); University of British Columbia
405 (Marianne Vidler, Jing (Larry) Li, Jeff Bone, Mai-Lei (Maggie) Woo Kinshella, Domena Tu,
406 Ash Sandhu, Kelly Pickerill); Imperial College London (Ben Barratt)

407

408 **Conflicts of Interest**

409 None declared.

410

411 **Funding Source**

412 This work was supported by Medical Research Council UK Research and Innovation [grant
413 numbers MR/P027938/1, MC_PC_20028 and MC_PC_19084]. The funders had no role in
414 the study design; collection, analysis and interpretation of data; or writing of the manuscript
415 and decision to publish.

416

417 **Ethical Approval**

418 This study was reviewed by the institutional review board, Scientific Coordinating
419 Committee, of the MRCG at LSHTM and ethical approval granted by The Gambia
420 Government/MRCG Joint Ethics Committee and the LSHTM Observational Ethics

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

421 Committee, ethics ref 22628. All participants provided broad written-informed consent for
422 participation in the PRECISE project and use of their biological samples in future health
423 research. The work described was carried out in accordance with the Declaration of Helsinki
424 for research involving human participants.

425

426 **References**

427

- 428 [1] Singh D and Yi SV. On the origin and evolution of SARS-CoV-2. *Exp Mol Med*,
429 2021. **53**(4): p. 537-547.
- 430 [2] World Health Organization. COVID-19 Weekly Epidemiological Update. Edition 72.
431 28 December 2021. [https://www.who.int/publications/m/item/weekly-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---28-december-2021)
432 [epidemiological-update-on-covid-19---28-december-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---28-december-2021) [accessed 8 August 2022].
- 433 [3] WHO Director-General's opening remarks at the media briefing on COVID-19 - 11
434 March 2020. [https://www.who.int/director-general/speeches/detail/who-director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
435 [general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
436 [accessed 30th June 2021].
- 437 [4] Adepoju P. Nigeria responds to COVID-19; first case detected in sub-Saharan Africa.
438 *Nat Med*, 2020. **26**(4):444-448.
- 439 [5] Frost I, Osen G., Craig J, Hauck S, Kalanxhi E, Gatalo O, et al. COVID-19 in West
440 Africa: National Projections of Total and Severe Infections Under Different
441 Lockdown Scenarios. Center for Disease Dynamics, Economics & Policy.
442 Department of Emergency Medicine, Johns Hopkins School of Medicine. 2020.
443 <https://cddep.org/wp-content/uploads/2020/07/West-Africa.pdf> [accessed 6 July
444 2021].

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

- 445 [6] Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and
446 Neonatal Morbidity and Mortality Among Pregnant Women With and Without
447 COVID-19 Infection: The INTERCOVID Multinational Cohort Study. *JAMA Pediatr.*
448 2021; **175**(8):817-826.
- 449 [7] Median age of the population of Africa from 2000 to 2030. Statista.
450 [https://www.statista.com/statistics/1226158/median-age-of-the-population-of-](https://www.statista.com/statistics/1226158/median-age-of-the-population-of-africa/#:~:text=In%202022%2C%20the%20median%20age,it%20was%20around%2017%20years)
451 [africa/#:~:text=In%202022%2C%20the%20median%20age,it%20was%20around%20](https://www.statista.com/statistics/1226158/median-age-of-the-population-of-africa/#:~:text=In%202022%2C%20the%20median%20age,it%20was%20around%2017%20years)
452 [17%20years](https://www.statista.com/statistics/1226158/median-age-of-the-population-of-africa/#:~:text=In%202022%2C%20the%20median%20age,it%20was%20around%2017%20years). [accessed 2 February 2023].
- 453 [8] Czeisler ME, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, et al. Delay or
454 Avoidance of Medical Care Because of COVID-19-Related Concerns - United States.
455 June 2020. *MMWR Morb Mortal Wkly Rep.* 2020;**69**(36):1250-1257.
- 456 [9] Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, Nardone A, et al. SARS-CoV-2
457 infection in Africa: a systematic review and meta-analysis of standardised
458 seroprevalence studies, from January 2020 to December 2021. *BMJ Glob Health.*
459 2022;**7**(8).
- 460 [10] Kribi S, Toure F, Mendes A, Sanou S, Some A, Aminou AM, et al. Multicountry
461 study of SARS-CoV-2 and associated risk factors among healthcare workers in Côte
462 d'Ivoire, Burkina Faso and South Africa. *Transactions of The Royal Society of*
463 *Tropical Medicine and Hygiene.* 2023;**117**(3):179-188.
- 464 [11] Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High
465 prevalence of pre-existing serological cross-reactivity against severe acute respiratory
466 syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. *Int J Infect Dis.*
467 2021;**102**:577-583.

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

- 468 [12] Lapidus S, Liu F, Casanovas-Massana A, Dai Y, Huck JD, Lucas , et al. Plasmodium
469 infection is associated with cross-reactive antibodies to carbohydrate epitopes on the
470 SARS-CoV-2 Spike protein. *Sci Rep.* 2022; **12**(1):22175.
- 471 [13] World Health Organisation. 26 May 2020. Population-based age-stratified
472 seroepidemiological investigation protocol for coronavirus 2019 (COVID-19)
473 infection. Version 2.0. [https://www.who.int/publications/i/item/WHO-2019-nCoV-](https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2)
474 [Seroepidemiology-2020.2](https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2) [accessed 24 March 2023].
- 475 [14] Nkuba Ndaye A, Hoxha A, Madinga J, Marien J, Peeters M, Leendertz FH, et al.
476 Challenges in interpreting SARS-CoV-2 serological results in African countries. *Lancet*
477 *Glob Health.* 2021; **9**(5):e588-e589.
- 478 [15] Our World in Data. Historical estimates of population, combined with the projected
479 population to 2100 based on UN's medium variant scenario.
480 <https://ourworldindata.org/grapher/population-past-future?tab=chart&country=GMB>
481 [accessed 26 July 2022].
- 482 [16] von Dadelszen, P, Flint-O'Kane M, Poston L, Craik R, Russell D, Tribe RM, et al. The
483 PRECISE (PREgnancy Care Integrating translational Science, Everywhere) Network's
484 first protocol: deep phenotyping in three sub-Saharan African countries. *Reprod Health.*
485 2020;**17** Suppl 1:51.
- 486 [17] Sanneh B, Sanneh S, Lareef-Jah S, Darboe B, Dibba LL, Manjang LF, et al. Practice of
487 preventive measures and vaccine hesitance for COVID 19 among households in The
488 Gambia, 2021: Study protocol. *PLoS One.* 2022; **17**(8):e0270304.
- 489 [18] The Gambia COVID-19 Outbreak Situational Report No. 452. Epidemiology and
490 Disease Control Unit, Ministry of Health, The Gambia. [https://www.moh.gov.gm/wp-](https://www.moh.gov.gm/wp-content/uploads/2022/09/GMB-COVID-19-Situational-Report-452_2022_10th_24th_September_2022.pdf)
491 [content/uploads/2022/09/GMB-COVID-19-Situational-Report-](https://www.moh.gov.gm/wp-content/uploads/2022/09/GMB-COVID-19-Situational-Report-452_2022_10th_24th_September_2022.pdf)
492 [452_2022_10th_24th_September_2022.pdf](https://www.moh.gov.gm/wp-content/uploads/2022/09/GMB-COVID-19-Situational-Report-452_2022_10th_24th_September_2022.pdf) [accessed 11 October 2022].

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

- 493 [19] Kanteh A, Jallow HS, Manneh J, Sanyang B, Kujabi MA, Ndure SL, et al. Genomic
494 epidemiology of SARS-CoV-2 infections in The Gambia: an analysis of routinely
495 collected surveillance data between March, 2020, and January, 2022. *Lancet Glob
496 Health*. 2023;**11**(3):e414-e424.
- 497 [20] Abatan B, Agboghroma O, Akemoke F, Antonio M, Awokola B, Bittaye M, et al.
498 Intense and Mild First Epidemic Wave of Coronavirus Disease, The Gambia. *Emerg
499 Infect Dis*. 2021;**27**(8):2064-2072.
- 500 [21] The Gambia COVID-19 Outbreak Situational Report No. 413. Epidemiology and
501 Disease Control Unit, Ministry of Health, The Gambia. [https://www.moh.gov.gm/wp-
502 content/uploads/2021/12/GMB-COVID-19-Situational-
503 Report_2021_25_26th_December_No-413.pdf](https://www.moh.gov.gm/wp-content/uploads/2021/12/GMB-COVID-19-Situational-Report_2021_25_26th_December_No-413.pdf) [accessed 26 July 2022].
- 504 [22] The Gambia Bureau of Statistics. Distribution of Population by Gender and LGA.
505 IHS 2015/2016. [https://www.gbosdata.org/topics/population-and-
506 demography/distribution-of-population-by-gender-and-lga](https://www.gbosdata.org/topics/population-and-demography/distribution-of-population-by-gender-and-lga) [accessed 27 July 2022].
- 507 [23] WANTAI SARS-CoV-2 Ab ELISA. Ref WS-1096. Beijing Wantai Biological
508 Pharmacy Enterprise Co., Ltd. No. 31 Kexueyuan Road, Changping District, Beijing,
509 102206 China. <https://www.fda.gov/media/140929/download> [accessed 27 July
510 2022].
- 511 [24] EUROIMMUN US. Anti-SARS-CoV-2 ELISA (IgG) Instruction for use. 1
512 Bloomfield Ave Mountain Lakes, New Jersey 07046.
513 [https://cdnmedia.eurofins.com/eurofinsus/media/1711222/ei_2606g_a_us_c01_igg_ce
514 .pdf](https://cdnmedia.eurofins.com/eurofinsus/media/1711222/ei_2606g_a_us_c01_igg_ce.pdf) [accessed 27 July 2022].
- 515 [25] EUROIMMUN a PerkinElmer company. Anti-SARS-CoV-2 NCP ELISA (IgG) EI
516 2606-9601-2 G. Medizinische Labordiagnostika AG. Seekamp 31. 23560 Lubeck
517 Germany. <https://www.coronavirus->

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

- 518 diagnostics.com/documents/Indications/Infections/Coronavirus/EI_2606_D_UK_C.p
519 df [accessed 12 August 2022].
- 520 [26] StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX:
521 StataCorp LLC.
- 522 [27] Mohammed NI, Mackenzie G, Ezeani E, Sidibeh M, Jammeh L, Sarwar G, et al.
523 Quantifying excess mortality during the COVID-19 pandemic in 2020 in The Gambia:
524 a time-series analysis of three health and demographic surveillance systems. *Int J Infect*
525 *Dis.* 2022; **128**:61-68.
- 526 [28] Talla C, Loucoubar C, Roka JL, Barry A, Ndiaye S, Diarra M, et al. Seroprevalence of
527 anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional
528 survey, between October and November 2020. *IJID Reg.* 2022;**3**:117-125.
- 529 [29] Konu YR, Conde S, Gbeasor-Komlanvi F, Sadio AJ, Tchankoni MK, Anani J, et al.
530 SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household
531 survey, May-June, 2021. *BMC Public Health.* 2022;**22**(1)2294.
- 532 [30] Emmerich P, Murawski C, Ehmen C, von Possel R, Pekarek N, Oestereich L, et al.
533 Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum
534 samples of African origin. *Trop Med Int Health.* 2021;**26**(6)621-631.
- 535 [31] Navaratnam AMD, Shrotri M, Nguyen V, Braithwaite I, Beale S, Byrne TE, et al.
536 Nucleocapsid and spike antibody responses following virologically confirmed SARS-
537 CoV-2 infection: an observational analysis in the Virus Watch community cohort. *Int J*
538 *Infect Dis.* 2022;**123**:104-111.
- 539 [32] Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-
540 based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United
541 States. *EClinicalMedicine.* 2021;**36**100902.

PeriCOVID: SARS-CoV-2 seroprevalence in pregnant women from Farafenni, The Gambia

- 542 [33] Downe S, Finlayson K, Tuncalp □, Metin Gulmezoglu A. What matters to women: a
543 systematic scoping review to identify the processes and outcomes of antenatal care
544 provision that are important to healthy pregnant women. BJOG. 2016;**123**(4):529-39.
545
546
547

periCOVID manuscript: results

Table 1a. Overall SARS-CoV-2 seroprevalence (IgM and IgG combined) at each study period.

Area	Period	Positive (Total) n (N)	Prevalence (95% CI)
Overall	Pre-Pandemic1	1 (112)	0.9 (0.2, 4.9)
	Pre-Pandemic2	3 (73)	4.1 (1.4, 11.4)
	Post-Wave1	65 (209)	31.1 (25.2, 37.7)
	Post-Wave2	130 (208)	62.5 (55.8, 68.8)
	Post-Wave3	181 (201)	90 (85.1, 93.5)
Urban	Pre-Pandemic1	1 (87)	1.1 (0.2, 6.2)
	Pre-Pandemic2	3 (68)	4.4 (1.5, 12.2)
	Post-Wave1	23 (77)	29.9 (20.8, 40.8)
	Post-Wave2	64 (97)	66 (56.1, 74.6)
	Post-Wave3	68 (75)	90.7 (82, 95.4)
Rural	Pre-Pandemic1	0 (25)	0
	Pre-Pandemic2	0 (5)	0
	Post-Wave1	42 (132)	31.8 (24.5, 40.2)
	Post-Wave2	66 (111)	59.5 (50.2, 68.1)
	Post-Wave3	113 (126)	89.7 (83.1, 93.9)

Table 1b. Comparison of SARS-CoV-2 seroprevalence (IgM and IgG combined) between *post-wave* time-periods.

Name	Period	Estimate (95% CI)	P-value
Prevalence Ratio			
WANTAI SARS-CoV-2	PostWave2 vs PostWave1	2 (1.5, 2.7)	<0.001
	PostWave3 vs PostWave1	2.9 (2.2, 3.7)	<0.001
	PostWave3 vs PostWave2	1.4 (1.3, 1.7)	<0.001
Prevalence Difference			
WANTAI SARS-CoV-2	PostWave2 vs PostWave1	31.4 (20.3, 42.5)	<0.001
	PostWave3 vs PostWave1	58.9 (49.8, 68.1)	<0.001
	PostWave3 vs PostWave2	27.5 (18, 37.1)	<0.001

Figure 1.




Figure 2. (a)




Figure 2 (b)




Figure 3.





Figure 4.



New infections



PeriCOVID manuscript: Figure Legend

Figure 1: SARS-CoV-2 transmission waves embedding study design.

A schematic design showing sampling time periods and sample-sizes per time period. The shadowed areas are the period of sample collection. Samples were grouped into two *Pre-pandemic* and three pandemic time periods linked to the first three COVID-19 waves as *Post-wave* time periods.

Figure 2: SARS-CoV-2 seroprevalence at each study period: (a) Overall, (b) Stratified by rural and urban health facilities (WANTAI Test).

Chart showing SARS-CoV-2 total IgG/IgM antibodies' seroprevalence with 95% CI (a) per time period and (b) for rural and urban Farafenni in the *Post-wave* time periods

Figure 3: Prevalence of SARS-CoV-2 IgG sero-positivity against S-specific protein IgG and NCP-specific protein IgG.

Chart showing SARS-CoV-2 spike S1-subunit protein specific [S-IgG (blue)] and nucleocapsid protein specific [NCP-IgG (grey)] antibodies' prevalence and 95% CI per time period.

Figure 4: New infections in percentages at each of the *Post-wave* periods.

Chart showing percentage of new infections at each *Post-wave* time period.

Supplementary Figure 1: Testing algorithm for SARS-CoV-2 seroprevalence by WANTAI and EUROIMMUN Commercial Kits.

Chart showing assay work flow. All samples positive for WANTAI test were tested using both EUROIMMUN S-specific IgG and EUROIMMUN NCP-specific IgG kits.